Structural Analysis of Impurities in Pharmaceuticals Using Trap-Free 2D HPLC and the LCMS-9030

Importance of the Topic

The management and structural identification of trace impurities in pharmaceutical products are critical for ensuring safety, efficacy, and regulatory compliance. Conventional HPLC methods with nonvolatile buffers can hinder direct LC/MS analysis, requiring time-consuming method transfers and risking loss of impurity information. A trap-free two-dimensional HPLC approach coupled with high-accuracy mass spectrometry addresses these challenges by preserving established separation conditions while enabling seamless MS detection.

Objectives and Study Overview

This study demonstrates an integrated workflow for the structural analysis of atorvastatin calcium impurities. Key goals include:

• Transferring nonvolatile HPLC conditions on-line to LC/MS without re-optimization.
• Capturing and fractionating impurity peaks in a trap-free 2D system.
• Applying quadrupole time-of-flight mass spectrometry (LCMS-9030) for accurate mass measurement and MS/MS structural elucidation.

Methodology and Instrumentation

The experiment uses a trap-free two-dimensional HPLC configuration connected to the LCMS-9030:

• First dimension HPLC: Shim-pack VP-ODS column; nonvolatile citric acid buffer with acetonitrile and tetrahydrofuran; UV detection at 254 nm.
• Peak capture: A switching valve directs fractions into a 20 μL loop without trapping agents.
• Second dimension HPLC: Shim-pack XR-ODS column; volatile mobile phases (10 mmol/L ammonium formate/water and acetonitrile); rapid gradient elution.
• Mass spectrometry: Shimadzu LCMS-9030 Q-TOF; ESI in positive and negative modes; full scan and MS/MS acquisition.

Main Results and Discussion

Using this system, 16 peaks including the main atorvastatin component were fractionated and analyzed. High mass accuracy (typically <1 ppm error) was achieved for both [M+H]+ and [M-H]– ions. MS/MS experiments, exemplified by impurity F, provided detailed fragmentation patterns and enabled confident structural assignments. The on-line transfer preserved original elution order and ensured detection of late-eluting or coeluting impurities that might be lost in method transfer.

Benefits and Practical Applications

This trap-free 2D HPLC–LC/MS platform offers:

• Direct use of established nonvolatile HPLC methods for impurity screening without manual buffer exchange.
• High throughput fractionation and analysis of trace impurities.
• Enhanced confidence in impurity identification through accurate mass and MS/MS data.
• Reduced risk of missing coeluting or low-abundance impurities.

Future Trends and Potential Applications

Advancements may include:

• Automated data processing and AI-driven structural elucidation.
• Integration with high-resolution 3D chromatography for complex mixtures.
• Application to other pharmaceutical classes and biopharmaceuticals.
• Development of universal trap-free interfaces for diverse chromatographic modes.

Conclusion

The combination of trap-free two-dimensional HPLC and the LCMS-9030 Q-TOF enables efficient and accurate structural analysis of pharmaceutical impurities under original HPLC conditions. This approach streamlines workflows, preserves separation fidelity, and enhances impurity characterization capabilities.

References

• Iida T., Inohana Y. Structural Analysis of Impurities in Pharmaceuticals Using Trap-Free 2D HPLC and the LCMS-9030. Shimadzu Application Note No. C185, First Edition March 2019.